The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
HOPA 2018 | Progression is progression! The importance of monitoring the efficacy of immunotherapy in NSCLC
Recently, due to the revolution of immunotherapy in the treatment of non–small cell lung cancer (NSCLC), more drugs are being licensed to treat patients in the second-line setting. Although overall survival in these patients has been shown to increase, the same can not be said for the rate of progression-free survival. Here, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, discusses the importance of carefully monitoring these patients during chemotherapy. This interview was recorded at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
